According to the findings, 33.4% of the women who received Cervarix had cleared HPV infection after six months, compared with 31.6% in the control group (Hildesheim et al., JAMA, 8/15). After one year, 48.8% of women who received Cervarix had cleared the infection, compared with about 49.8% who had not received the vaccine. The study also found that most HPV infections, regardless of the strain, clear spontaneously over a period of six months to two years.
"You should not get [Cervarix] because you want to treat an existing infection," Hildesheim said. He added, "The question that has not yet been answered is whether protecting [a woman] from reinfection of a virus that she has previously been infected with, and successfully cleared, will in fact reduce that woman's risk of getting cervical precancer and cancer".
GSK spokesperson Liad Diamond, said the results of the study are "completely expected." GSK and Merck, which makes the HPV vaccine Gardasil, said their vaccines are not intended to treat existing infections, adding that the study's findings confirm their companies' research.
Source-Kaiser Family Foundation
LIN/B